Insurance Coverage for Psychedelic Therapy
Study at a glance
AI-extracted from the abstract| Characteristics | Theoretical or philosophical paper |
|---|---|
| Topics | Psychedelic-assisted therapy |
| Key points | Argues that the reimbursement landscape for psychedelic therapies will be shaped by temporary CPT codes, on-label FDA indications, third-party administration models, and drug-plus-therapy billing structures, and recommends adopting Spravato's coverage and patient-assistance strategies. |
Abstract
As psychedelic-assisted therapies advance through the FDA approval pipeline, the question of who will pay for them is moving from academic to urgent. Experts project that MDMA-assisted therapy for PTSD will cost upwards of $11,000-$12,000 per course of treatment-a price tag that, absent insurance, places these therapies out of reach for many of the patients most likely to benefit. This essay examines how the psychedelic-therapy reimbursement landscape is shaping up by looking closely at the one psychedelic medicine already widely covered: Janssen's intranasal esketamine product, Spravato. It then analyzes the principal mechanisms likely to shape coverage for future psychedelic therapies: the AMA's new (and temporary) Current Procedural Terminology codes for in-person psychedelic monitoring; the strong industry preference for on-label, FDA-approved indications; emerging ancillary-benefit arrangements such as Enthea's third-party administration; and the novel "drug-plus-therapy" billing structure that MDMAassisted therapy will require. The essay concludes with recommendations for psychedelic-therapy companies, drawn from Spravato's playbook of broad insurance coverage, streamlined copayment programs, and independent patientassistance foundations.
Comparable studies
Other theoretical and historical papers on psychedelic-assisted therapy, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| Theorizing that Psychedelic Assisted Therapy May Play a Role in the Treatment of Trauma-Induced Personality Disorders. | 2024 | Theoretical or philosophical paper | |
| Learning to Let Go: A Cognitive-Behavioral Model of How Psychedelic Therapy Promotes Acceptance | 2020 | Theoretical or philosophical paper | |
| Awe: a putative mechanism underlying the effects of classic psychedelic-assisted psychotherapy | 2018 | Theoretical or philosophical paper | |
| Ethical and legal issues in psychedelic harm reduction and integration therapy | 2021 | Theoretical or philosophical paper | |
| Towards psychedelic apprenticeship: Developing a gentle touch for the mediation and validation of psychedelic-induced insights and revelations. | 2022 | Theoretical or philosophical paper |